Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | RAD52 | P43351 | 3/20 | 0.66 |
| ▸ | NSD2 | O96028 | 2/20 | 0.66 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282645 | 0.80 | RAD52 (1.00) | POLBRAD52NSD2RCE1KMT2A | |
| SCHEMBL30933280 | 0.80 | RAD52 (1.00) | POLBRAD52NSD2RCE1KMT2A | |
| SCHEMBL4072787 | 0.78 | KMT2A (0.62) | POLBNSD2KMT2AMEN1MAPT | |
| SCHEMBL4071997 | 0.70 | MPO (0.71) | POLBRAD52NSD2RCE1KMT2A | |
| SCHEMBL30593620 | 0.70 | ALDH1A1 (0.71) | KMT2AMEN1MAPTKDM4EALDH1A1 | |
| SCHEMBL30593621 | 0.70 | KDM4E (0.77) | KMT2AMEN1MAPTKDM4EALDH1A1 | |
| SCHEMBL30593623 | 0.69 | KDM4E (0.57) | POLBRAD52KMT2AMEN1MAPT | |
| SCHEMBL16171086 | 0.69 | NSD2 (0.79) | POLBRAD52NSD2RCE1KMT2A | |
| SCHEMBL4075245 | 0.68 | POLB (0.63) | POLBRAD52NSD2RCE1KMT2A | |
| SCHEMBL4256228 | 0.68 | POLB (0.69) | POLBRAD52NSD2RCE1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | claimed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | ABCG2, ATP5ME, ATP5MG | POLB 315/4885RAD52 1352/4885NSD2 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.